leukotoxin and Leukemia--Myeloid

leukotoxin has been researched along with Leukemia--Myeloid* in 2 studies

Other Studies

2 other study(ies) available for leukotoxin and Leukemia--Myeloid

ArticleYear
Leukotoxin kills rodent WBC by targeting leukocyte function associated antigen 1.
    Comparative medicine, 2013, Volume: 63, Issue:4

    Leukotoxin is a protein that is secreted by Aggregatibacter actinomycetemcomitans and that primarily targets the active form of leukocyte function associated antigen 1 (LFA1) on WBC. Because of its specificity for WBC, leukotoxin is being developed as a novel biologic treatment for hematologic malignancies and autoimmune-inflammatory diseases. Early studies indicated that leukotoxin is specific for WBC from humans and Old World primates. In the current study, we used in vivo and in vitro assays to show that leukotoxin has a wider host range than previously believed and can kill rodent WBC. Administration of leukotoxin to rats and mice resulted in a rapid drop in WBC number but had no effect on RBC or platelet counts. Using LFA1-knockout mice, we showed that leukotoxin-mediated depletion of WBC is dependent on LFA1. In addition, similar to its effect on human monocytes, leukotoxin kills murine myeloid leukemia via a lysosome-mediated pathway that is dependent on cathepsin D. This newly described broader host range of leukotoxin enables the biology of the protein to be studied in rodent species and offers the possibility of using rodent models for evaluating the therapeutic efficacy of leukotoxin in various diseases.

    Topics: Animals; Blood Platelets; Cell Line; Disease Models, Animal; Erythrocyte Count; Erythrocytes; Exotoxins; Leukemia, Myeloid; Leukocyte Count; Leukocytes; Lymphocyte Function-Associated Antigen-1; Mice; Mice, Inbred C57BL; Mice, Knockout; Platelet Count; Rats; Rats, Sprague-Dawley

2013
Killing of human myelomonocytic leukemia and lymphocytic cell lines by Actinobacillus actinomycetemcomitans leukotoxin.
    Infection and immunity, 1988, Volume: 56, Issue:5

    The purified leukotoxin of Actinobacillus actinomycetemcomitans kills human leukemic cell lines (e.g., HL-60, U937, and KG-1) and human T- and B-cell lines (e.g., JURKAT, MOLT-4, Daudi, and Raji) in a dose- and time-dependent manner. The 50% effective doses for these cell lines are similar to those established for human polymorphonuclear leukocytes and monocytes. In contrast, other human and nonhuman tumor cell lines are not susceptible to the leukotoxin. These human leukemia and lymphoid cell lines will serve as useful model systems with which to study the molecular specificity and mechanism(s) of action of the actinobacillus leukotoxin.

    Topics: Actinobacillus; Animals; Cell Survival; Dose-Response Relationship, Drug; Exotoxins; Humans; Immunotherapy; Leukemia, Myeloid; Mice; Microscopy, Electron; Rats; T-Lymphocytes, Cytotoxic; Tumor Cells, Cultured

1988